Skip Navigation

COVID-19 Update

Due to interest in the COVID-19 vaccines, we are experiencing an extremely high call volume. Please understand that our phone lines must be clear for urgent medical care needs. We are unable to accept phone calls to schedule COVID-19 vaccinations at this time. When this changes, we will update this website. Our vaccine supply remains limited. Read all COVID-19 Vaccine Information.

Patient Care Options | Visitor Guidelines | Coronavirus Information | Self-Checker | Get Email Alerts


Clinical Research

For a complete list of available clinical trials, search the database at the Johns Hopkins Institute for Clinical and Translational Research. You can search by condition, researcher or doctor’s name.

A Post-Market, Prospective, Multi-Center, Open-Label, Single Arm Clinical Evaluation of the Integra TitanTM Modular Shoulder System 2.5 for Primary Shoulder Joint Replacement (IRB00169712)

Objective: To evaluate 2-year implant survivorship in subjects who receive the TSS-2.5 when used for primary shoulder arthroplasty.
Principle Investigator: Umasuthan Srikumaran, M.D., M.P.H., M.B.A.
Eligibility Criteria: Candidate for total shoulder arthroplasty
Contact: Sanjana Vattigunta (443-516-1550 or
Learn more about this study.

Post-operative Pain Control Following Shoulder Surgery

Objective: Evaluate overall pain medication consumption following surgical treatment for shoulder pathology
Principle Investigator: Umasuthan Srikumaran, M.D., M.P.H., M.B.A.
Eligibility Criteria: Opioid-naive adults age 18-90 years old planning to undergo surgical treatment for shoulder pathology with Dr. Uma Srikumaran
Contact: Sanjana Vattigunta (443-516-1550 or

OPTIMIZE Low Back Pain

Objective: Improve health care for patients with chronic lower back pain (LBP) and increase the likelihood that patients obtain outcomes that matter most to them
Principle Investigator: Richard Skolasky, Sc.D.
Eligibility Criteria: Adults age 18 - 64 years old, meets NIH Task Force definition of chronic LBP, had a healthcare visit for LBP in the past 90 days and have moderate levels of pain and disability
Contact: Tricia Kirkhart (410-502-4453 or
Learn more about this study.

Dysport® (abobotulinumtoxinA) as an Adjunctive Treatment to Bracing in the Management of Adolescent Idiopathic Scoliosis (AIS)

Objective: To evaluate the combined effect of botulinum toxin A (administered as Dysport®) and bracing in children with adolescent idiopathic scoliosis
Principle InvestigatorPaul D. Sponseller, M.D.
Eligibility Criteria: Diagnosed with AIS, 10 - 16 year old children.
Contact: Vivian Tran and Varun Puvanesarajah (410-955-3136 or

Participants in this study will be compensated.
Learn more about this study.

back to top button